发布求助
文献互助 智能选刊 最新文献

Medical oncology and tumor pharmacotherapy最新文献

筛选
英文 中文
Notes &news and mini-reviews 笔记&新闻和迷你评论
Medical oncology and tumor pharmacotherapy Pub Date : 1992-09-01 DOI: 10.1007/BF02987748
{"title":"Notes &news and mini-reviews","authors":"","doi":"10.1007/BF02987748","DOIUrl":"https://doi.org/10.1007/BF02987748","url":null,"abstract":"","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 1","pages":"155-156"},"PeriodicalIF":0.0,"publicationDate":"1992-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987748","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"52296348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-Glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine a containing protocols p -糖蛋白在难治性血液学肿瘤中的表达和维拉帕米或环孢素a的耐药规避方案
Medical oncology and tumor pharmacotherapy Pub Date : 1992-06-01 DOI: 10.1007/BF02989661
M. Beksaç, H. Akan, Ha-neul Ko, O. Lhan, E. Ertürk, Aynur Güneyl, Yem Kzünal, Orhan S.arda
{"title":"P-Glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporine a containing protocols","authors":"M. Beksaç, H. Akan, Ha-neul Ko, O. Lhan, E. Ertürk, Aynur Güneyl, Yem Kzünal, Orhan S.arda","doi":"10.1007/BF02989661","DOIUrl":"https://doi.org/10.1007/BF02989661","url":null,"abstract":"","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 1","pages":"101-105"},"PeriodicalIF":0.0,"publicationDate":"1992-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989661","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"52321196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Radiation-induced thyroid cancer. 辐射诱发的甲状腺癌。
Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02987755
P Hall
{"title":"Radiation-induced thyroid cancer.","authors":"P Hall","doi":"10.1007/BF02987755","DOIUrl":"https://doi.org/10.1007/BF02987755","url":null,"abstract":"<p><p>Thyroid cancer was the first solid tumor that showed an increased incidence among the Japanese A-bomb survivors and recently published data indicated an increase of thyroid cancer among children in Belarus. The annual thyroid cancer rate between 1986 and 1989 was 4 cases and 2 years later a 14-fold increase was found. That study has several methodological weaknesses but is nevertheless alarming. The present paper reviews the current epidemiological knowledge on radiation-induced thyroid cancer, and discusses the methodological difficulties. It is concluded that low doses of brief gamma radiation induce thyroid cancer in juveniles. No study has yet proven a relationship between protracted low dose exposure and thyroid cancer or an increased thyroid cancer risk among adults after exposure to any form of ionizing radiation. Thyroid cancer seems to have a somewhat shorter latency period than other solid tumors and the dose-response relationship seems to be linear. The most important issues in radiation protection concerning thyroid cancer are the risk of a thyroid cancer following low dose and/or protracted exposure to ionizing radiation and following 131I exposure in childhood.</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 4","pages":"183-9"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987755","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12515333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Stomatocytosis as a presenting symptom of myelodysplasia. 口细胞增生症是骨髓发育不良的主要症状。
Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02987759
K Konstantopoulos, G Vassilopoulos, S Adamides, M Alexandrakis, J Zervas
{"title":"Stomatocytosis as a presenting symptom of myelodysplasia.","authors":"K Konstantopoulos,&nbsp;G Vassilopoulos,&nbsp;S Adamides,&nbsp;M Alexandrakis,&nbsp;J Zervas","doi":"10.1007/BF02987759","DOIUrl":"https://doi.org/10.1007/BF02987759","url":null,"abstract":"","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 4","pages":"213-4"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987759","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12515337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. 对术后用新城疫病毒溶瘤液治疗的II期恶性黑色素瘤患者进行10年随访。
Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02987752
W A Cassel, D R Murray
{"title":"A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.","authors":"W A Cassel,&nbsp;D R Murray","doi":"10.1007/BF02987752","DOIUrl":"https://doi.org/10.1007/BF02987752","url":null,"abstract":"<p><p>Newcastle disease virus oncolysate was examined as an adjunctive immunotherapeutic agent in the postsurgical management of 83 cases of Stage II malignant melanoma. At this time, all the patients have been under observation for at least 10 years, and over 60% are alive and free of recurrent disease. Older studies in the United States report postsurgical survival figures for Stage II cases of 5-15%. More contemporary studies indicate a 33% survival at 10 years. The unusual disease-free survival periods in the present study, including exceptional survivals in 21 patients with head and neck disease and six cases with cerebral metastases, suggest a unique role for the administration of Newcastle disease virus oncolysate in the management of Stage II malignant melanoma patients.</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 4","pages":"169-71"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987752","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12514709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 115
Survival in metastatic breast cancer after combination of radio-chemotherapy and hyperthermia. 转移性乳腺癌放化疗和热疗联合治疗后的生存率。
Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01
P Pontiggia
{"title":"Survival in metastatic breast cancer after combination of radio-chemotherapy and hyperthermia.","authors":"P Pontiggia","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 2","pages":"107-9"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12515437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of pineal melatonin and melatonin-induced-immuno-opioids in murine leukemogenesis. 松果体褪黑素和褪黑素诱导的免疫阿片在小鼠白血病发生中的作用。
Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989659
A Conti, N Haran-Ghera, G J Maestroni
{"title":"Role of pineal melatonin and melatonin-induced-immuno-opioids in murine leukemogenesis.","authors":"A Conti,&nbsp;N Haran-Ghera,&nbsp;G J Maestroni","doi":"10.1007/BF02989659","DOIUrl":"https://doi.org/10.1007/BF02989659","url":null,"abstract":"<p><p>The relationship between the pineal gland, melatonin and melatonin-induced-immuno-opioids with the response of C57Bl/6 mice to A-RadLV induced T cell lymphomas was investigated. Mice were injected at day 0 with A-RadLV and from day 10 they were treated chronically with melatonin 4 mg/kg body weight, naltrexone 1 mg/kg or phosphate buffered saline, throughout the experiment. In another protocol, groups of mice were a) surgical pinealectomized at day-14, b) functional pinealectomized (24:24 hours light) from day -20 and c) sham pinealectomized. At day 0 each group was inoculated intrathymically with A-RadLV. The results show that melatonin accelerated (p < 0.005) leukemogenesis whereas the surgical pinealectomy and the functional pinealectomy delayed it (p < 0.005 and p < 0.01). Moreover, the action of melatonin was blocked by naltrexone (p < 0.005), indicating the involvement of melatonin-induced-immuno-opioids in the development of the lymphomas.</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 2","pages":"87-92"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989659","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12515442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Antibody-directed therapy of multidrug-resistant tumor cells. 多药耐药肿瘤细胞的抗体靶向治疗。
Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989648
T Efferth, M Volm
{"title":"Antibody-directed therapy of multidrug-resistant tumor cells.","authors":"T Efferth,&nbsp;M Volm","doi":"10.1007/BF02989648","DOIUrl":"https://doi.org/10.1007/BF02989648","url":null,"abstract":"<p><p>The major obstacle to effective cancer chemotherapy is the resistance of tumor cells to cytostatic agents. Tumor cells frequently express a multidrug-resistance (MDR) phenotype. In an effort to devise new strategies to overcome MDR, antibody-directed approaches for the eradication of MDR cells have been developed. Experimental data have shown that multidrug-resistant tumor cells can be efficiently killed by monoclonal antibodies, immunotoxins, or bispecific antibodies. The current experimental results indicate that an antibody-directed therapeutic approach to eradication of MDR cells might be a promising adjunct to conventional chemotherapy of cancer patients.</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 1","pages":"11-9"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989648","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12460051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Leukemic progression as process of adaptation (theoretical model). 作为适应过程的白血病进展(理论模型)。
Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02989653
I V Alekseyev
{"title":"Leukemic progression as process of adaptation (theoretical model).","authors":"I V Alekseyev","doi":"10.1007/BF02989653","DOIUrl":"https://doi.org/10.1007/BF02989653","url":null,"abstract":"<p><p>On the basis of an assumption that leukemic progression is a process of adaptation of normal hemopoiesis to the effect of the leukemic clone, a theoretical model of leukemia development is built. General conclusions are as follows: the possibility of reaching remission depends upon suppression of normal hemopoiesis by cytostatics in a system of two cell populations: the duration of remission depends upon suppression of the leukemic clone; the quantity of blast cells of marrow in remission can exceed 5 per cent.</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 1","pages":"47-50"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02989653","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12513791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Case report: acute polymyositis in a patient with chronic graft vs. host disease. 病例报告:慢性移植物抗宿主病患者急性多发性肌炎。
Medical oncology and tumor pharmacotherapy Pub Date : 1992-01-01 DOI: 10.1007/BF02987746
J L Ascensao, R B Mascarenhas, A Mittelman, T Ahmed
{"title":"Case report: acute polymyositis in a patient with chronic graft vs. host disease.","authors":"J L Ascensao,&nbsp;R B Mascarenhas,&nbsp;A Mittelman,&nbsp;T Ahmed","doi":"10.1007/BF02987746","DOIUrl":"https://doi.org/10.1007/BF02987746","url":null,"abstract":"<p><p>Chronic graft versus host disease (cGVHD) is a multisystemic condition which occurs in 25 to 40% of patients undergoing allogeneic bone marrow transplantation. A 31 year old male developed acute polymyositis one year in the setting of cGVHD etc. after allogeneic bone marrow transplantation. A viral etiology could not be proven. This presumably represented a manifestation of cGVHD. His clinical condition improved with immunosuppression and he remains asymptomatic, off therapy.</p>","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"9 3","pages":"149-50"},"PeriodicalIF":0.0,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987746","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12515128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信